Rubric Capital Management LP
Position in EPRX — Eupraxia Pharmaceuticals Inc.
CIK 1687509
NEW YORK, NY
Position in EPRX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$5,004,070
New position
Shares Held
691,170
first reported quarter
Ownership
1.06%
of shares outstanding
% of Portfolio
0.06%
of 13F equity value
Holder Rank
#11
of 54 holders
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Rubric Capital Management LP holds $938,577,278 across 18 Biotechnology names. EPRX ranks #17 (0.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ARQT |
Arcutis Biotherapeutics, Inc.
|
8,271,577 | $194,878,354 | |
| 2 | ZYME |
Zymeworks Inc.
|
7,000,000 | $175,280,000 | |
| 3 | ROIV |
Roivant Sciences Ltd.
|
5,000,000 | $138,500,000 | |
| 4 | SPRY |
ARS Pharmaceuticals, Inc.
|
8,000,000 | $64,240,000 | |
| 5 | MGTX |
MeiraGTx Holdings plc
|
7,000,000 | $60,620,000 | |
| 6 | PRTA |
Prothena Corp Public Ltd Co
|
5,000,000 | $48,600,000 | |
| 7 | PTGX |
Protagonist Therapeutics, Inc
|
427,998 | $45,110,989 | |
| 8 | TRVI |
Trevi Therapeutics, Inc.
|
3,712,373 | $44,288,609 |
All Filings in EPRX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $5,004,070 | 691,170 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||